Cipher Pharmaceuticals Inc (CPH) Rating Lowered to Hold at Bloom Burton
Cipher Pharmaceuticals Inc (TSE:CPH) (NASDAQ:CPHR) was downgraded by research analysts at Bloom Burton from a “buy” rating to a “hold” rating in a research note issued on Monday.
Several other equities research analysts also recently commented on CPH. CIBC increased their price objective on shares of Cipher Pharmaceuticals from C$7.50 to C$8.00 in a research report on Friday, May 12th. TD Securities increased their price target on shares of Cipher Pharmaceuticals from C$5.50 to C$6.50 in a research note on Monday.
Shares of Cipher Pharmaceuticals (TSE:CPH) opened at 5.24 on Monday. Cipher Pharmaceuticals has a 12-month low of $3.50 and a 12-month high of $6.00. The stock’s 50 day moving average price is $5.40 and its 200-day moving average price is $4.96. The company’s market cap is $138.92 million.
ILLEGAL ACTIVITY NOTICE: “Cipher Pharmaceuticals Inc (CPH) Rating Lowered to Hold at Bloom Burton” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/08/15/cipher-pharmaceuticals-inc-cph-rating-lowered-to-hold-at-bloom-burton.html.
In related news, Director Harold Morton Wolkin acquired 15,000 shares of the stock in a transaction dated Tuesday, May 30th. The stock was bought at an average price of C$5.57 per share, for a total transaction of C$83,550.00. Also, insider John Mull acquired 5,000 shares of the stock in a transaction dated Monday, June 12th. The stock was bought at an average price of C$5.55 per share, with a total value of C$27,750.00. Insiders have purchased a total of 97,700 shares of company stock worth $542,370 over the last ninety days.
About Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.
Receive News & Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.